CLINICAL ROLE -
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
Study Shows Older Patients With AML Respond to Treatment With VEN-HMA
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
FDA Approves Updated Label for Altuviiio to include Full Data on Pediatric Patients With Hemophilia A
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
Commercializing CRISPR/Cas9 Therapy: FDA Approval of Exa-Cel Marks Milestone in Treatment Development
FDA Grants 510(k) Clearance for Rika Plasma Donation System